|
86 Companies |
|
137 Products |
|
137 Products |
|
85 Mechanisms of Action |
|
4 Trials |
|
2019 News |
|
| «12...1011121314151617181920...3940» |
- aripiprazole / Generic mfg., amisulpride / Generic mfg.
Enrollment closed, Trial primary completion date: Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS) (clinicaltrials.gov) - Dec 6, 2014
P=N/A, N=120, Active, not recruiting, Sponsor: University of Copenhagen
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> May 2014
- Trial completion, Trial primary completion date, HEOR, Cost effectiveness: HEPIMEC: HEalth Promotion Intervention in MEntal Health Care (clinicaltrials.gov) - Dec 6, 2014
P=N/A, N=742, Completed, Sponsor: University Ghent
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> May 2014 Active, not recruiting --> Completed | Trial primary completion date: May 2012 --> May 2013
- Trial primary completion date: Cognitive Remediation for First Episode of Psychosis Patients (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=48, Recruiting, Sponsor: University of Manchester
Active, not recruiting --> Completed | Trial primary completion date: May 2012 --> May 2013 Trial primary completion date: Dec 2014 --> Mar 2015
- Trial primary completion date: Pain and Schizophrenia (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=107, Recruiting, Sponsor: University Hospital, Strasbourg, France
Trial primary completion date: Dec 2014 --> Mar 2015 Trial primary completion date: Jan 2014 --> Aug 2016
- Trial primary completion date: MAMAO2: Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications - 2 (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=120, Active, not recruiting, Sponsor: Department of Veterans Affairs
Trial primary completion date: Jan 2014 --> Aug 2016 Trial primary completion date: Sep 2014 --> Jun 2016
- | Clopixol (zuclopenthixol) / Lundbeck, Serlect (sertindole) / Lundbeck, Abbott
New P4 trial: Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients (clinicaltrials.gov) - Dec 5, 2014
P4, N=25, Recruiting, Sponsor: Technische Universit
- |||||||||| New P3 trial, Head-to-Head: TaSCS: Task Sharing for the Care of Severe Mental Disorders in a Low-income Country (clinicaltrials.gov) - Dec 5, 2014
P3, N=324, Not yet recruiting, Sponsor: Addis Ababa University
- || Enrollment closed, Trial primary completion date, Patient reported outcomes: CIAS PRO: Schizophrenia Cognition Scale Development (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=125, Active, not recruiting, Sponsor: New England Research Institutes
Trial primary completion date: Sep 2014 --> Jun 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Jan 2015
- Trial completion: The Family Cognitive Adaptation Training Manual: A Test of Effectiveness (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=40, Completed, Sponsor: Centre for Addiction and Mental Health
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Jan 2015 Active, not recruiting --> Completed
- ||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
Trial completion: A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia (clinicaltrials.gov) - Dec 5, 2014
P3, N=766, Completed, Sponsor: Forest Laboratories
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date: Metabolic Syndrome in Patients With First-episode Schizophrenia (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=203, Completed, Sponsor: Aarhus University Hospital
Active, not recruiting --> Completed Recruiting --> Completed | N=100 --> 203 | Trial primary completion date: Dec 2012 --> Apr 2013
- |||||| Caplyta (lumateperone) - Intra / Cellular Therapies
Enrollment open: A Trial to Assess the Antipsychotic Efficacy of ITI-007 (clinicaltrials.gov) - Dec 4, 2014
P3, N=440, Recruiting, Sponsor: Intra-Cellular Therapies, Inc.
Recruiting --> Completed | N=100 --> 203 | Trial primary completion date: Dec 2012 --> Apr 2013 Not yet recruiting --> Recruiting
- || Lu AF11167 / Lundbeck
Trial primary completion date: Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia (clinicaltrials.gov) - Nov 28, 2014
P1, N=72, Recruiting, Sponsor: H. Lundbeck A/S
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2014 --> Jan 2015
- Trial primary completion date: Deep Brain Stimulation (DBS) for the Management of Treatment Refractory Negative Symptoms in Schizophrenia (clinicaltrials.gov) - Nov 28, 2014
P1, N=6, Recruiting, Sponsor: Centre for Addiction and Mental Health
Trial primary completion date: Oct 2014 --> Jan 2015 Trial primary completion date: Sep 2014 --> Sep 2016
- Enrollment closed: SGE-PsyScan: Supporting Primary Care in Diagnosis and Choice of Treatment for Patients With Psychosocial Symptoms: SGEPsyScan. (clinicaltrials.gov) - Nov 28, 2014
P=N/A, N=648, Active, not recruiting, Sponsor: Maastricht University Medical Center
Trial primary completion date: Sep 2014 --> Sep 2016 Recruiting --> Active, not recruiting
- ||||| bitopertin (DISC-1459) / Disc Medicine
Enrollment closed, Trial primary completion date: A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306) (clinicaltrials.gov) - Nov 25, 2014
P3, N=598, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Completed --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Feb 2015
- ||||| bitopertin (DISC-1459) / Disc Medicine
Enrollment closed, Trial primary completion date: A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (clinicaltrials.gov) - Nov 25, 2014
P3, N=623, Active, not recruiting, Sponsor: Hoffmann-La Roche
Completed --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Feb 2015 Completed --> Active, not recruiting | Trial primary completion date: Jul 2014 --> Jan 2016
- New P4 trial: Curcumin Addition to Antipsychotic Treatment in Chronic Schizophrenia Patients (clinicaltrials.gov) - Nov 24, 2014
P4, N=40, Not yet recruiting, Sponsor: Beersheva Mental Health Center
- SKL-15508 / SK Bio
Trial primary completion date: A Safety, Tolerability, PK and PD Study of Multiple Oral Doses of SKL15508 in Subjects With Stable Schizophrenia (clinicaltrials.gov) - Nov 23, 2014
P1/2, N=48, Recruiting, Sponsor: SK Life Science
Completed --> Active, not recruiting | Trial primary completion date: Jul 2014 --> Jan 2016 Trial primary completion date: Dec 2014 --> Jun 2015
- iloperidone / Generic mfg.
Trial primary completion date: Assessing the Effects of Fanapt (clinicaltrials.gov) - Nov 23, 2014
P4, N=19, Terminated, Sponsor: Northwestern University
Trial primary completion date: Dec 2014 --> Jun 2015 Trial primary completion date: Dec 2014 --> Feb 2014
- |||| osoresnontrine (BI 409306) / Boehringer Ingelheim
Enrollment open: A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment. (clinicaltrials.gov) - Nov 23, 2014
P2, N=516, Recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Dec 2014 --> Feb 2014 Not yet recruiting --> Recruiting
- Enrollment open, Trial primary completion date: Correlation Between Clinical Deterioration in Schizophrenic Patients and Hair Cortisol Levels (clinicaltrials.gov) - Nov 19, 2014
P=N/A, N=40, Recruiting, Sponsor: Shalvata Mental Health Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2015 --> Jun 2015
- | raloxifene hydrochloride / Generic mfg.
Trial completion, Trial primary completion date: FSJD-RAL-2010: Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women (clinicaltrials.gov) - Nov 19, 2014
P3, N=78, Completed, Sponsor: Fundaci
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2015 --> Jun 2015 Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jul 2014
- risperidone / Generic mfg.
Trial completion, Enrollment change: POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia (clinicaltrials.gov) - Nov 19, 2014
P2, N=7, Completed, Sponsor: PharmaNeuroBoost N.V.
Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jul 2014 Recruiting --> Completed | N=60 --> 7
- |||| ziprasidone / Generic mfg.
Trial completion, Trial primary completion date: Effectiveness of Ziprasidone for Patients With Schizophrenia (clinicaltrials.gov) - Nov 19, 2014
P4, N=67, Completed, Sponsor: Soonchunhyang University Hospital
Recruiting --> Completed | N=60 --> 7 Recruiting --> Completed | Trial primary completion date: Dec 2011 --> Jun 2013
- Enrollment closed: Effects of Systematic Patient Feedback on Therapy Outcome (clinicaltrials.gov) - Nov 18, 2014
P=N/A, N=120, Active, not recruiting, Sponsor: Norwegian University of Science and Technology
Recruiting --> Completed | Trial primary completion date: Dec 2011 --> Jun 2013 Recruiting --> Active, not recruiting
- | Trial completion: Transcranial Current Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia (clinicaltrials.gov) - Nov 18, 2014
P=N/A, N=26, Completed, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Active, not recruiting Recruiting --> Completed
- clozapine / Generic mfg.
Enrollment open, Trial primary completion date: Clozapine Plasma Levels and the Relationship to the Genetic Polymorphism in Shizophrenic Patients (clinicaltrials.gov) - Nov 17, 2014
P4, N=20, Recruiting, Sponsor: Tirat Carmel Mental Health Center
Recruiting --> Completed Not yet recruiting --> Recruiting | Trial primary completion date: May 2013 --> May 2015
- Disalcid (salsalate) / Bausch Health
Trial primary completion date: Salsalate as an Adjunctive Treatment for Patients With Schizophrenia (clinicaltrials.gov) - Nov 14, 2014
P4, N=15, Recruiting, Sponsor: University of Massachusetts, Worcester
Not yet recruiting --> Recruiting | Trial primary completion date: May 2013 --> May 2015 Trial primary completion date: May 2014 --> Aug 2015
- Enrollment closed: GMGWP: Get Moving and Get Well - Pilot Study (clinicaltrials.gov) - Nov 13, 2014
P=N/A, N=30, Active, not recruiting, Sponsor: Department of Veterans Affairs
Trial primary completion date: May 2014 --> Aug 2015 Recruiting --> Active, not recruiting
- | Caplyta (lumateperone) - Intra / Cellular Therapies
New P2 trial: Receptor Occupancy of ITI-007 Using Positron Emission Tomography (PET) in Patients With Stable Schizophrenia (clinicaltrials.gov) - Nov 12, 2014
P2, N=14, Recruiting, Sponsor: Intra-Cellular Therapies, Inc.
- ondansetron / Generic mfg.
Trial completion, Trial primary completion date: Randomized Double Blind Placebo Control Study in Patients With Schizophrenia (clinicaltrials.gov) - Nov 12, 2014
P2, N=303, Completed, Sponsor: Pakistan Institute of Learning and Living
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Aug 2012 --> Jun 2013
- ||| PT150 / The Pop Test & Palisades Therap
Trial initiation date: A Study to Determine the Efficacy and Safety of 2 Doses of Org 34517 as Adjunctive Therapy in Subjects With Psychotic Major Depression (28130)(P05845) (clinicaltrials.gov) - Nov 11, 2014
P2, N=273, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed | Trial primary completion date: Aug 2012 --> Jun 2013 Initiation date: Oct 2004 --> Jul 2004
- || Rexulti (brexpiprazole) / Lundbeck, Otsuka
Enrollment change: Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo (clinicaltrials.gov) - Nov 7, 2014
P=N/A, N=380, Enrolling by invitation, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Initiation date: Oct 2004 --> Jul 2004 N=520 --> 380
- Enrollment closed, Trial primary completion date: Lifestyle Intervention for Diabetes and Weight Management in Psychosis (clinicaltrials.gov) - Nov 7, 2014
P=N/A, N=120, Active, not recruiting, Sponsor: Centre for Addiction and Mental Health
N=520 --> 380 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Dec 2015
- ||||| iloperidone / Generic mfg.
Enrollment closed: REPRIEVE: Relapse Prevention Study in Patients With Schizophrenia (clinicaltrials.gov) - Nov 7, 2014
P3, N=303, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Dec 2015 Recruiting --> Active, not recruiting
- Trial completion, Enrollment change: An Acceptance-Based Behavioral Intervention vs. Nutritional Counselling for Weight Loss in Psychotic Illness (clinicaltrials.gov) - Nov 7, 2014
P=N/A, N=16, Completed, Sponsor: Centre for Addiction and Mental Health
Recruiting --> Active, not recruiting Recruiting --> Completed | N=12 --> 16
- || Rexulti (brexpiprazole) / Lundbeck, Otsuka
Trial completion: Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment (clinicaltrials.gov) - Nov 7, 2014
P3, N=48, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting --> Completed | N=12 --> 16 Active, not recruiting --> Completed
- Trial completion: Neurophysiological Targets for Cognitive Training in Schizophrenia (clinicaltrials.gov) - Nov 7, 2014
P=N/A, N=60, Completed, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed Recruiting --> Completed
- |||| iloperidone / Generic mfg.
Trial primary completion date: REPRIEVE: Relapse Prevention Study in Patients With Schizophrenia (clinicaltrials.gov) - Nov 6, 2014
P3, N=303, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Trial primary completion date: Sep 2015 --> Dec 2015
- olanzapine / Generic mfg.
Trial completion, Phase classification, Enrollment change: Diabetes in Neuropsychiatric Disorders (clinicaltrials.gov) - Nov 6, 2014
P1/2, N=30, Completed, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Trial primary completion date: Sep 2015 --> Dec 2015 Recruiting --> Completed | Phase classification: PN/A --> P1/2 | N=328 --> 30
- ||| Enrollment closed: A Safety and Effectiveness Study of Paliperidone Palmitate in Chinese Patients With Schizophrenia (clinicaltrials.gov) - Nov 5, 2014
P4, N=353, Active, not recruiting, Sponsor: Xian-Janssen Pharmaceutical Ltd.
Recruiting --> Completed | Phase classification: PN/A --> P1/2 | N=328 --> 30 Recruiting --> Active, not recruiting
- || Rexulti (brexpiprazole) / Lundbeck, Otsuka
Trial completion, Enrollment change, Trial primary completion date: Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms (clinicaltrials.gov) - Nov 5, 2014
P3, N=37, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=50 --> 37 | Trial primary completion date: Sep 2014 --> Jun 2014
- |||||||||| Caplyta (lumateperone) - Intra / Cellular Therapies
New P3 trial: A Trial to Assess the Antipsychotic Efficacy of ITI-007 (clinicaltrials.gov) - Nov 4, 2014
P3, N=440, Not yet recruiting, Sponsor: Intra-Cellular Therapies, Inc.
- ||||| osoresnontrine (BI 409306) / Boehringer Ingelheim
New P2 trial: A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment. (clinicaltrials.gov) - Nov 4, 2014
P2, N=516, Not yet recruiting, Sponsor: Boehringer Ingelheim
- Trial completion, Enrollment change, Trial primary completion date: Cerebral Reorganization in Schizophrenia (clinicaltrials.gov) - Nov 4, 2014
P=N/A, N=80, Completed, Sponsor: University of Konstanz
Active, not recruiting --> Completed | N=50 --> 37 | Trial primary completion date: Sep 2014 --> Jun 2014 Recruiting --> Completed | N=20 --> 80 | Trial primary completion date: Dec 2013 --> Apr 2014
- ||||||| bitopertin (DISC-1459) / Disc Medicine
Trial completion, Trial primary completion date: A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306) (clinicaltrials.gov) - Nov 4, 2014
P3, N=598, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Completed | N=20 --> 80 | Trial primary completion date: Dec 2013 --> Apr 2014 Active, not recruiting --> Completed | Trial primary completion date: Feb 2015 --> Sep 2014
- ||||||| bitopertin (DISC-1459) / Disc Medicine
Trial completion, Trial primary completion date: A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307) (clinicaltrials.gov) - Nov 4, 2014
P3, N=595, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | Trial primary completion date: Feb 2015 --> Sep 2014 Active, not recruiting --> Completed | Trial primary completion date: Jan 2014 --> Jul 2014
- ||||||| bitopertin (DISC-1459) / Disc Medicine
Trial completion, Trial primary completion date: A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (clinicaltrials.gov) - Nov 4, 2014
P3, N=625, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | Trial primary completion date: Jan 2014 --> Jul 2014 Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Jul 2014
- Trial completion: Enhancing Motivation To Quit Smoking In Smokers With Serious Mental Illness (clinicaltrials.gov) - Nov 4, 2014
P1, N=98, Completed, Sponsor: University of Medicine and Dentistry of New Jersey
Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Jul 2014 Active, not recruiting --> Completed